Stay updated on MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety

Sign up to get notified when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.
Latest website image capture
Clouds background image

Latest updates to the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:42:01.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the efficacy or safety evaluation of subcutaneous tildrakizumab (MK-3222) in participants with moderate-to-severe chronic plaque psoriasis.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:44.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying inclusion and exclusion criteria for participants with moderate-to-severe plaque psoriasis. Previously, no information was provided in this section.
    Difference
    26%
    Check dated 2024-05-22T20:53:59.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:29:50.000Z thumbnail image

Stay in the know with updates to MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety

Enter your email address, and we'll notify you when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.